Review Article
Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer
Table 9
The relationship between the development of rash and clinical outcome when using anti-EGFR mAbs in mCRC.
| Trial (first author) | KRAS | Protocol | Grade of rash | Results |
HR (95% CI) | value | PFS | OS |
| — (O’Callaghan et al.) [44] | WT | BSC versus | 0/1 | 1.9 mos. | 5 mos. | PFS: 0.57 (0.38–0.86) OS: 0.85 (0.56–1.31) | 0.008 0.46 | cetuximab
| 2.2 mos.
| 8 mos.
| WT | BSC versus | 2+ | 1.9 mos. | 5 mos. | PFS: 0.32 (0.21–0.49) OS: 0.52 (0.34–0.8) | <0.001 0.003 | cetuximab | 5.1 mos. | 9.8 mos. | MUT | BSC versus | 0/1 | 1.9 mos. | 5 mos. | PFS: 0.97 (0.65–1.46) OS: 1.47 (0.95–2.27) | 0.89 0.08 | cetuximab
| 1.8 mos. | 4.0 mos. | MUT | BSC versus | 2+ | 1.9 mos. | 5 mos. | PFS: 0.82 (0.52–1.3) OS: 0.82 (0.47–1.41) | 0.89 0.46 | cetuximab | 1.8 mos. | 6.6 mos. |
|
|
WT: wild type, MUT: mutated, PFS: progression-free survival, and OS: overall survival.
|